NCT04017455Active, not recruitingPhase 2
Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
In this study, patients with resectable rectal cancer will receive radiotherapy, followed by neoadjuvant bevacizumab and atezolizumab
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- First submitted
- 10 Jul 2019
- Start date
- 22 Oct 2019
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- The Netherlands Cancer Institute
- Diseases
- Colorectal cancer
- NCT number
- NCT04017455
- EU CT number
- 2024-517119-59-00
- EudraCT number
- 2018-002463-25
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 38
- From 22 Oct 2019 to the primary completion date, 31 Dec 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- prior radiation therapy for disease under study
- prior treatment with CD137 agonists or immune checkpoint blockade therapies
Other illness
- evidence of metastatic disease
- history of clinically significant cardiac or pulmonary dysfunction pregnancy or breastfeeding
- significant auto-immune disease
Other
- current or recent use of acetylsalicylic acid
Who the study is looking for
- signed informed consent
- patients age 18 years and older
- histologically confirmed adenocarcinoma of the rectum
- intermediate risk rectal cancer or low risk distal rectal cancer
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stichting OLVG Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Recruiting |
| Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.